ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed 08 December 8:00AM
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
42.20
Bid
41.80
Offer
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
fuagf fuagf 3 minutes ago
"President-elect Donald Trump’s transition team still has not sent policy advisers to coordinate with the federal
agencies he is preparing to take over, delaying preparations that could be key to executing his ambitious agenda

Your - https://www.msn.com/en-us/news/politics/tr
fza fza 4 minutes ago
Finer material....

Put that into the equation also.

What is the increase in size/weight of the cocoon in comparison to industry standards? How does it differ when boiled and harvested for reeling? Better or worse? Lots of unknowns hardly incorporated into the AI conv
KBLB
weedtrader420 weedtrader420 4 minutes ago
Why buy them when we’re making them. we make charts you follow them.
XRPUSD
oilin07 oilin07 4 minutes ago
https://bllbstock.com/
BLLB
KISSINGER KISSINGER 5 minutes ago
It doesnt work that way. The way it was gonna work with Local BTV when they were still around was based on impressions. If somebody clicks on a channel or program a Vast Tag appears. They were averaging with Local BTV 120,000,000 impressions per month. Usually you have 25% attrition with no click th
AHRO
fuagf fuagf 5 minutes ago
Don't kiss the hand, you carry germs

https://www.usnews.com/object/image/00000193-9d3b-d64a-abd3-dd7bc0950000/20241204edhan-a.jpg?update-time=1733512479116&size=responsiveGallery
trunkmonk trunkmonk 5 minutes ago
I used data to conclude this can go to $1500, i aint gonna justify it, cause its for me to know and anyone else to accept or not, actually dont care. I resisted Crypto for too long, even though most crypto is useless and completely a scam cause it has no intrinsic value, XRP, XLM, and BTC are some o
XRPUSD
al44 al44 5 minutes ago
Democrats suddenly embrace herd immunity

By Geoffrey P. Hunt

Biden should give pre-emptive pardons to all 74 million Kamala Harris voters. Why shouldn’t rank-and-file Democrats enjoy president-issued broad-spectrum immunity, too?

And so, only Joe Biden c
weedtrader420 weedtrader420 5 minutes ago
Yup, that’s what I’m saying I have a whole lot too,Not parting with☝️😎☝️🐳
XRPUSD
SilkRoad SilkRoad 6 minutes ago
I’m waiting for the day when a big boy announces DragonSilk sutures available for use in cardiovascular, ophthalmic, and neurological procedures. Kim mentioned this application a long time ago so I would think someone like Medtronic or J&J tested it to supplement or replace the silk already being u
KBLB
jetow jetow 6 minutes ago
Remember That!!!!!!!
KBLB
ddls ddls 7 minutes ago
Re: NONE, The Iranian "Carnac The Magnificent," tell us when BioElectronics will start making a profit?

My psychic ability tells me it will never make a profit because the debt is too large and sales will stay too small.

Please tell us Carnac.😎
BIEL
nowwhat2 nowwhat2 8 minutes ago
You can't BUY no charts like this........They're only just The BEST

https://investorshub.advfn.com/uimage/uploads/2024/12/7/mwvrdxrp_121212_7_CAPT_45d_7am_calvin_GREAT.jpg
XRPUSD
learningcurve2020 learningcurve2020 8 minutes ago
Posting negative comments on a company while refusing to invest (or invest more) actually makes perfect sense. Not sure why you're confused?? 
NWBO
oystersnbeer oystersnbeer 8 minutes ago
Far-right activists from Germany spent US election day at Trump’s Mar-a-Lago

https://cdn.britannica.com/29/187129-050-F55F3A5C/Nazi-Party-rally-Nurnberg-Germany-1933.jpg

https://www.theguardian.com/us-news/2024/dec/07/far-right-activists-from-germany-spent-us-election-d
TRUISM TRUISM 9 minutes ago
Staying on topic helps, if you want a proper response..

I see my acronym remains imbedded in your psyche after all this time...

Sorry about that. 😂🤣😂
KBLB
biotechinvestor1 biotechinvestor1 9 minutes ago
This is no competition. Greg Frost is one of the co-founders of Halozyme, co-inventor of human hyaluronidase and former CEO of halozyme.
HALO
oilin07 oilin07 9 minutes ago
bellbuckleholdings.com
BLLB
al44 al44 10 minutes ago
Trump effect: In the private sector, animal spirits are frolicking

By Noel S. Williams

Several companies in the consumer discretionary sector just reported robust quarterly earnings.

More importantly (for forward-looking markets), they raised their outlo
eyal2 eyal2 11 minutes ago
style="font-size: 16px"New from Blagman;
style="font-size: 16px"

style="font-size: 16px"

style="font-size: 16px"https://x.com/RBLAGGY/status/1865338832583065835?t=grd4HWWsjnDtDS3lODA_DQ&s=19
MWWC
havnagoodtime havnagoodtime 11 minutes ago
Yep...pump machine on full throttle.
DPLS
BDEZ BDEZ 11 minutes ago
Exactly.....
BDEZ BDEZ 12 minutes ago
Coming down the ladder holding a person.....unreal.

Your Recent History

Delayed Upgrade Clock